4.86
+0.83%
Close of 9 Nov 2026, in THB
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Inter Pharma PCL
Its shares trade on SET under the ticker IP.BK. It has been listed since 5 November 2019. In the fiscal year to 31 December 2025, it reported revenue of THB 2.19bn and net income of THB 122.4m. At that date it held total assets of THB 3.24bn and shareholders' equity of THB 2.06bn.
Inter Pharma PCL engages in the business of importing and distributing general health products. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2019-11-05. The firm is principally engaged in the importing, manufacturing and distribution of dietary supplement product for humans and animals. The company provides wellness and anti-aging products, aesthetic innovation products, animal health products and livestock products. The firm's segment includes Human healthcare, animal healthcare, and Hospital. Its wellness and anti-aging products include Probac7, Probac10 plus, TS6, Beta Glucan Plus, Pure Krill Oil, Astacurmin and YUUU Cleansing Mousse. Its aesthetic innovation products include Perfectha Complement, Perfectha Derm, Perfectha Deep and Perfectha Subskin. The firm's animal health products include Dr.Choice Cal-B, Dr.Choice Cardi-B, Petinol, Pet Select Senior, Pet Select Osteoflex and Malaseb Shampoo for dogs and cats. The company also offers pet foods for dogs and cats. Its subsidiaries include Inter Vetta Co., Ltd., and Modern Pharma Co., Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Care Products
- Listed since
- 5 Nov 2019
- Employees
- 282
- Website
- interpharma.co.th ↗
Leadership
Pay as last reported
- Prof. Dr. Udom KochinthornIndependent Chairman of the Board
- Dr. Songsawut Sak ChalathornChief Executive Officer, Director
- Ms. Supaporn PhithakpanitVice President - Accounting and Finance, Director
- Mrs. Naphon Dej AkkaratOperations Director, Director
- Mrs. Thanatphan ThianthipsiriDirector of Management
- Mrs. Sansanee ChaiyarojIndependent Director
- Mr. Kamtorn Sila-onIndependent Director
- Prof. Dr. Piyamitr SritharaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Inter Pharma PCL operates in the Consumer Staples sector with a focus on consumer products.
- The company employs 282 staff members to support its importing and distribution business.
- Its product portfolio includes dietary supplements for humans and animals such as Probac7 and Dr.Choice Cal-B.
Weaknesses
- The company is headquartered in a single location in Bangkok, Bangkok Metropolis.
- Inter Pharma PCL went public via an IPO in November 2019, indicating a relatively recent listing.
- The firm's operations are concentrated in Thailand, limiting its geographic diversification.
Opportunities
- The company can expand its wellness and anti-aging products like Pure Krill Oil and Astacurmin.
- Inter Pharma PCL may grow its aesthetic innovation products such as Perfectha Derm and Perfectha Deep.
- The firm can increase sales of its animal health products including Pet Select Senior and Malaseb Shampoo.
Threats
- Competition exists within the human healthcare segment where Inter Pharma PCL distributes general health products.
- The animal healthcare segment faces market pressures for products like Petinol and Dr.Choice Cardi-B.
- The Hospital segment requires continuous supply chain management for its distributed consumer products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.